Our study demonstrates that presumably, CPF-containing plasmas from FSGS patients induce podocyte lipid droplet accumulation and perilipin-2 expression, identifying perilipin-2 as a potential biomarker. The gene discussed is NR5A2; the disease is focal segmental glomerulosclerosis.